Friday, April 3, 2026
30.4 C
Bengaluru

Digital Noise to Digital Voice – A 4-Module Workshop for Pharma People

When Covid19 struck for the first time in March 2020, the pharma industry was not ready for the sudden and dramatic changes, that disrupted the healthcare industry completely.

And to deal with the sudden and dramatic changes, professionals in the pharma industry needed awareness, education, and knowledge sharing.

MedicinMan took up this responsibility in partnership with CredoWeb to create “Digital Excellence Pharma Academy” –DEPA and conducted 50+ online sessions with renowned Indian and International healthcare industry influencers as faculty members, from May 2020 to April 2021.

And DEPA1.0 was a great success!

Now is time to learn how to perform marketing and sales activities using the new technology in the New Normal on practice! 

We go into the why, how, and what of doing digital. If you were a Listener till now, you’ll be a Player now!

MedicinMan in partnership with CredoWeb is again coming up with the 2.0 version of our DEPA with international and Indian faculty – Dr. Peter Velev, a medical doctor and pharma industry veteran, Praful Akali, founder and CEO of Medulla Communications and Salil Kallianpur, pharma marketing veteran and digital brand coach.

The workshop sessions will be moderated by Anup Soans, Editor @ MedicinMan to discuss: International and Indian case studies Interactive Q & A sessions

We are launching DEPA 2.0 Workshop with four Modules beginning Saturday, October 30, 2021.

For registration and program details – https://medicinman.net/register-for-depa-2-0/

For any questions and how to join DEPA 2.0 please write to: anupsoans@medicinman.net

Hot this week

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Topics

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

As over 50 generic versions of the blockbuster weight-loss...
spot_img

Related Articles

spot_imgspot_img